Introduction {#s1}
============

During development, the heart undergoes a series of morphogenetic changes to form a functional cardiac wall structure ([@bib39]; [@bib53]). The outer wall of the developing ventricle consists of compact layer cardiomyocytes (CMs), while the inner wall consists of complex muscular ridges, termed trabeculae, which facilitate efficient cardiac contraction and oxygenation of the cardiac wall prior to the formation of coronary vessels ([@bib51]; [@bib53]). Disruption of ventricular wall morphogenesis is associated with congenital cardiac malformations, the most common type of birth defects ([@bib13]), yet the cellular and molecular mechanisms regulating this complex process remain unclear.

Neuregulin (NRG)/Erb-b2 receptor tyrosine kinase (ERBB) 2/4 signaling has been shown to be essential for cardiac trabeculation. *Nrg1*, *Erbb2* and *Erbb4* knockout mice ([@bib16]; [@bib29]; [@bib37]) and *nrg2a* ([@bib48]) and *erbb2* ([@bib31]) mutant fish fail to form trabeculae. ERBBs are members of the epidermal growth factor (EGF) receptor tyrosine kinase family. NRGs are expressed by the endocardium ([@bib5]; [@bib37]; [@bib17]; [@bib48]) and bind to ERBBs on CMs, triggering homo- or heterodimerization of ERBB family members and leading to activation of downstream pathways ([@bib50]). However, the targets of ERBB2 signaling that regulate CM behavior during trabeculation have not been identified.

Cardiac metabolism has been extensively studied in adult animals due to its central role in supplying energy for cardiac contraction ([@bib10]; [@bib25]). Adult CMs rely mostly on fatty acids as an energy substrate, and they are oxidized in mitochondria to generate ATP ([@bib12]). Under conditions of hypertrophic or ischemic stress, CMs revert to glycolytic metabolism ([@bib10]), which is characteristic of embryonic cardiomyocytes and uses glucose as a fuel. Besides its role in energy generation, little is known about the role of metabolism during cardiac development.

Here, using high-resolution single cell imaging in zebrafish, we first show that developing CMs undergo extensive shape changes during the formation of the trabecular layer. By modulating glucose metabolism pharmacologically, we show that glycolysis regulates these processes. Using CM-specific loss- and gain-of-function models as well as mutant animals compromised in their glycolytic activity, we identify a role for glycolysis in cardiac wall morphogenesis. This study provides new insights into the role of cardiac metabolism in cardiac development.

Results {#s2}
=======

Cardiomyocytes that enter the trabecular layer exhibit distinct behaviors {#s2-1}
-------------------------------------------------------------------------

During cardiac trabeculation in zebrafish and mouse, CMs delaminate from the compact layer to seed the trabecular layer ([@bib31]; [@bib60]; [@bib52]; [@bib24]; [@bib9]). Although CM behavior during trabeculation has been observed in zebrafish ([@bib52]; [@bib2]), the 3D morphology of single cardiomyocytes during the trabeculation process needs to be further explored. To this end, we performed 3D time-course imaging using chimeric hearts generated by cell transplantation. To label CM membranes and nuclei with EGFP and DsRed2 respectively, we used *Tg(myl7:EGFP-HRAS); Tg(myl7:nDsRed2)* cells as donors ([Figure 1a](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}). We found that delaminating CMs exhibit morphological changes as well as rearrangements of contact sites ([Figure 1b--c"](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1b--d"](#fig1s1){ref-type="fig"}; [Figure 1---videos 1](#fig1video1){ref-type="video"} and [2](#fig1video2){ref-type="video"}), while CMs remaining in the compact layer do not exhibit such changes ([Figure 1d--e"](#fig1){ref-type="fig"}). To examine cell-cell junctions during delamination, we analyzed N-cadherin (Cdh2), a major adherens junction component, at single cell resolution, and to this end used *Tg(myl7:EGFP-HRAS); Tg(myl7:cdh2-tdTomato)* cells as donors ([Figure 1---figure supplement 1e](#fig1s1){ref-type="fig"}). We observed that N-cadherin localizes to protruding membranes in delaminating CMs ([Figure 1---figure supplement 1f--g"](#fig1s1){ref-type="fig"}) and to the lateral membranes of compact layer CMs ([Figure 1---figure supplement 1h--i"](#fig1s1){ref-type="fig"}), in agreement with a previous report ([@bib2]). Next, we analyzed sarcomere structure during delamination using *Tg(myl7:LIFEACT-GFP); Tg(myl7:nDsRed2)* cells as donors. We found that CMs display partial sarcomere disassembly in their protrusions when entering the trabecular layer ([Figure 1f--g"](#fig1){ref-type="fig"}). These data indicate that delaminating CMs exhibit distinct behaviors including dynamic cell shape changes.

![Cardiomyocyte behavior during cardiac trabeculation.\
(**a**) Schematic of the transplantation experiment. (**b--e**) 3D time-course images of chimeric hearts; magnified view (**b', c', d', e'**) of area in white boxes and Y-Z plane images (**b", c", d", e"**) along white dashed lines (**b', c', d', e'**). CMs initially in the compact layer (**b', b"**) enter the trabecular layer (**c', c"**) exhibiting morphological changes and membrane protrusions (c'; arrowheads; *n* = 5 CMs); CMs remaining in the compact layer (**d', d", e', e"**) do not exhibit obvious morphological changes (*n* = 5 CMs). The same CMs are shown at 126 and 175 hpf as indicated in the images. (**f, g**) 3D time-course images of chimeric heart; magnified view (**f', f", g', g"**) of area in white boxes. CMs entering the trabecular layer exhibit partial disassembly of their sarcomeres (g'; arrowhead). Scale bars, 20 μm.](elife-50161-fig1){#fig1}

ERBB2 signaling activates glycolysis in cardiomyocytes {#s2-2}
------------------------------------------------------

To gain additional insight into the molecular mechanisms that regulate trabeculation, we focused on ERBB2 signaling which is essential for this process in both mouse ([@bib16]; [@bib29]; [@bib37]) and zebrafish ([@bib31]; [@bib46]; [@bib48]). In order to identify targets of ERBB2 signaling, we analyzed protein expression in a CM-specific transgenic mouse model inducibly expressing a constitutively active form of ERBB2 (CAERBB2) ([@bib11]). We found that upon CAERBB2 overexpression (OE), several glycolytic enzymes were upregulated, while mitochondrial proteins and oxidative phosphorylation (OXPHOS)-related enzymes were downregulated ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). We also tested the effects of *Erbb2* OE, which like *CAErbb2* OE, activates downstream signaling ([@bib43]), on the expression of glycolytic enzyme genes in rat neonatal CMs, and found that many of them were upregulated ([Figure 2a](#fig2){ref-type="fig"}). Notably, we found that *Erbb2* OE in rat neonatal CMs greatly upregulated the levels of pyruvate kinase M2 (PKM2), a key glycolytic enzyme, ([Figure 2b and c](#fig2){ref-type="fig"}), and increased glycolytic activity as evidenced by measuring extracellular acidification rate (ECAR) ([Figure 2d](#fig2){ref-type="fig"}). NRG1 stimulation also activated glycolysis in rat neonatal CMs ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). These findings are also supported by a study analyzing changes in mRNA levels in *caErbb2* OE mouse hearts ([@bib21]). Moreover, we treated zebrafish embryos with an Erbb2 inhibitor ([Figure 2e](#fig2){ref-type="fig"}), which has been shown to severely affect trabeculation ([Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}) ([@bib31]; [@bib46]), and found that the cardiac expression of glycolytic enzyme genes was downregulated ([Figure 2b](#fig2){ref-type="fig"}). Altogether, these data indicate that ERBB2 signaling activates glycolysis in CMs.

![ERBB2 signaling activates glycolysis in cardiomyocytes.\
(**a**) qPCR analysis of mRNA levels of glycolytic enzyme genes in control and *Erbb2* overexpressing (OE) rat neonatal CMs (*n* = 3). Error bars, s.e.m. (**b**) Staining for PKM2, CTNI and DNA (DAPI) in control and *Erbb2* OE rat neonatal CMs; arrowheads point to PKM2+ CMs. (**c**) Western blot analysis of PKM2 levels in control and *Erbb2* OE rat neonatal CMs. (**d**) Extracellular acidification rate (ECAR) analysis in control and *Erbb2* OE rat neonatal CMs; glycolytic capacity shown on the right (*n* = 7). Error bars, s.d. (**e**) qPCR analysis of mRNA levels of glycolytic enzyme genes in DMSO and Erbb2 inhibitor treated zebrafish hearts (*n* = 3). Error bars, s.e.m.; \*p\<0.05 and \*\*p\<0.001 by two-tailed unpaired *t*-test. NS, not significant. Scale bar, 20 μm.\
Figure 2---source data 1.Mass spectrometry data.P7 WT and CAERBB*2* OE mouse hearts were isolated and protein expression levels analyzed by mass spectrometry. All presented proteins are statistically significant at p\<0.05.\
Figure 2---source data 2.Primer sequences for qPCR analysis.Primer sequences used in [Figure 2a and e](#fig2){ref-type="fig"}.\
Figure 2---source data 3.Mean Ct values of qPCR analysis in [Figure 2a and e](#fig2){ref-type="fig"}.](elife-50161-fig2){#fig2}

Glycolysis regulates cardiomyocyte delamination during development {#s2-3}
------------------------------------------------------------------

In order to analyze the role of glycolysis during trabeculation, we first focused on pyruvate metabolism. The pyruvate dehydrogenase complex (PDC) catalyzes the conversion of pyruvate to acetyl-coenzyme A (acetyl-CoA), which enters the tricarboxylic acid cycle ([@bib61]). Pyruvate dehydrogenase kinases (PDKs) inhibit PDC activity and enhance glycolysis in CMs ([@bib62]) and cancer cells ([@bib26]; [@bib32]; [@bib28]; [@bib44]), thereby regulating the switch between glycolysis and OXPHOS ([@bib61]). Our analyses show that ERBB2 signaling positively regulates *Pdk3* gene as well as protein expression ([Figure 2a and b](#fig2){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Thus, we hypothesized that PDK3 was one of the key enzymes regulating glycolysis in delaminating CMs in response to Erbb2 signaling. Consistent with this model, we found that the PDK inhibitor dichloroacetate (DCA) led to a significant reduction in the number of CMs in the trabecular layer ([Figure 3a](#fig3){ref-type="fig"}). Of note, this phenotype is similar to the one caused by Erbb2 inhibition ([Figure 3a](#fig3){ref-type="fig"}).

![Glycolysis regulates cardiac trabeculation.\
(**a**) Confocal images (mid-sagittal sections) of 77 hpf hearts treated with DMSO, dichloroacetate (DCA) or Erbb2 inhibitor; magnified view of area in white boxes shown below; arrowheads point to CMs in the trabecular layer; percentage of CMs in the trabecular layer shown on the right (*n* = 5--7 ventricles). (**b**) Confocal images (mid-sagittal sections) of 77 hpf *Tg(myl7:BFP-CAAX)* alone or in combination with *Tg(myl7:pdha1aSTA-P2A-tdTomato)* or *Tg(myl7:pdk3b-P2A-tdTomato)* hearts; magnified view of area in white boxes shown below; arrowheads point to CMs in the trabecular layer; percentage of CMs in the trabecular layer shown on the right (*n* = 5--7 ventricles). (**c--e"**) Staining for CTNI, N-cadherin and DNA (DAPI) in control (**c**), *Pdk3* (**d**) and *Erbb2* (**e**) OE rat neonatal CMs; magnified view of area in yellow (**c', d', e'**) and white (**c", d", e"**) boxes; percentage of CMs exhibiting membrane protrusions shown on the right (*n* = 3 individual experiments; each value corresponds to an average of 30 CMs). *Pdk3* and *Erbb2* OE causes rat neonatal CMs to exhibit membrane protrusions (d', e'; arrows) and cell-cell junction rearrangements (d', e'; arrowheads). Error bars, s.e.m.; \*p\<0.05 and \*\*p\<0.001 by ANOVA followed by Tukey's HSD test. Scale bars, 20 μm.](elife-50161-fig3){#fig3}

We next focused on *pyruvate dehydrogenase E1 alpha 1 subunit a* (*pdha1a*), which encodes a catalytic subunit of the PDC. Analysis of CM-specific loss of *Pdha1* in mice has revealed the importance of PDC activity for OXPHOS ([@bib55]). We generated a *Tg(myl7:pdha1aSTA-P2A-tdTomato)* line to overexpress an activated form of Pdha1a in CMs. This activated form of Pdha1a (Pdha1aSTA) contains mutations in its phosphorylation sites and thus is not inhibited by PDK. As a result, glycolysis is reduced and OXPHOS enhanced, as previously shown in cancer cells ([@bib20]; [@bib14]). Notably, larvae expressing this activated form of Pdha1a exhibited a significant decrease in the number of CMs in the trabecular layer ([Figure 3b](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). We also generated a *Tg(myl7:pdk3b-P2A-tdTomato)* line to overexpress *pdk3b* in CMs and thereby promotes glycolysis ([@bib32]), and found that these transgenic larvae exhibited a significant increase in the number of CMs in the trabecular layer ([Figure 3b](#fig3){ref-type="fig"}). Next, we tested whether the modulation of glycolysis affected CM proliferation and found that *Tg(myl7:pdha1aSTA-P2A-tdTomato)* or *Tg(myl7:pdk3b-P2A-tdTomato)* larvae did not exhibit a significant change compared to WT in the percentage of mVenus-gmnn+ CMs ([Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}). Furthermore, we examined whether the modulation of glycolysis affected CM morphology in rat neonatal CMs in culture and found that *Pdk3* overexpression led to the induction of membrane protrusions ([Figure 3d and d'](#fig3){ref-type="fig"}), as well as cell-cell junction rearrangements ([Figure 3d--d"](#fig3){ref-type="fig"}). Similar effects were also observed following *Erbb2* overexpression ([Figure 3e--e"](#fig3){ref-type="fig"}). Together, these data suggest that CM morphological changes regulated by glycolysis are important for delamination.

In order to further assess the role of glycolysis in trabeculation, we focused on zebrafish *pkm2* to analyze a glycolytic enzyme mutant model. Loss of *PKM2* has been shown to impair glycolysis in endothelial cells ([@bib54]), and PKM2 expression has been associated with glycolysis and cell growth in cancer cells ([@bib4]). Moreover, in rat neonatal CMs, *Erbb2* OE upregulated *Pkm2* ([Figure 2b and c](#fig2){ref-type="fig"}). Mammalian *Pkm* encodes two splice variants (M1 and M2 isoforms); PKM2 plays an important role in glycolysis, while PKM1 promotes OXPHOS ([@bib4]; [@bib33]; [@bib63]). Zebrafish *pkma2*, a splice variant of *pkma*, and *pkmb* are the orthologues of mammalian *Pkm2* ([@bib54]). During early development, *pkma* is expressed in the heart, head, spinal cord and blood vessels, while *pkmb* is highly expressed in the somites ([Figure 4---figure supplement 1a](#fig4s1){ref-type="fig"}). At later stages, *pkmb* becomes clearly expressed in the heart ([Figure 4---figure supplement 1b](#fig4s1){ref-type="fig"}; [@bib19]). We examined *pkma2; pkmb* double mutants in which Pkma1, which drives pyruvate metabolism via OXPHOS, remains intact, and found that loss of *pkma2* and *pkmb* impaired trabeculation ([Figure 4---figure supplement 1c](#fig4s1){ref-type="fig"}). We did not find evidence for increased CM apoptosis in *pkma2; pkmb* double mutants compared to WT ([Figure 4---figure supplement 1d](#fig4s1){ref-type="fig"}). In order to examine the CM-specific role of *pkma2* and *pkmb* in trabeculation, we performed cell transplantation experiments whereby *pkma2; pkmb* double heterozygous and double mutant cells were transplanted into WT embryos ([Figure 4a](#fig4){ref-type="fig"}). We found a significantly lower percentage of double mutant versus double heterozygous CMs in the trabecular layer of mosaic hearts ([Figure 4b--c](#fig4){ref-type="fig"}), indicating the importance of these genes in trabeculation. We also counted the number of trabecular CMs in these chimeric hearts and observed no significant deviation from WT ([Figure 4---figure supplement 1e](#fig4s1){ref-type="fig"}). Altogether, these results indicate that glycolysis plays important and CM-autonomous roles during trabeculation.

![Loss of *pkm2* impairs cardiac trabeculation.\
(**a**) Schematic of the transplantation experiment. (**b, b'**) 3D and mid-sagittal section images of chimeric hearts using *pkma2^+/-^; pkmb^+/-^; Tg(myl7:EGFP-HRAS)* (**b**) and *pkma2^-/-^; pkmb^-/-^; Tg(myl7:EGFP-HRAS)* (**b'**) cells as donors; magnified view of area in white boxes shown below. (**c**) Percentage of donor-derived trabecular CMs (*n* = 10 ventricles). Error bars, s.e.m.; \*p\<0.05 by two-tailed unpaired *t*-test. Scale bars, 20 μm.](elife-50161-fig4){#fig4}

Discussion {#s3}
==========

During trabeculation, CMs exhibit membrane protrusions ([@bib52]) and rearrange their cell-cell junctions ([@bib2]; [@bib38]). Our 3D single CM imaging clearly reveals that CMs that enter the trabecular layer change their shape, similar to migrating cells, and lose cell-cell adhesion, indicating that they undergo phenotypic changes. Epithelial cells exhibit cellular plasticity as they change shape, and lose cell-cell adhesion and apicobasal polarity - a phenotypic transformation called epithelial to mesenchymal transition (EMT) ([@bib41]; [@bib58]; [@bib57]). Recent studies suggest that endothelial cells can also undergo phenotypic changes towards mesenchymal-like cells ([@bib36]; [@bib59]; [@bib42]; [@bib8]; [@bib27]). Before the onset of trabeculation, compact layer CMs exhibit apicobasal polarity, and then some of them depolarize and subsequently delaminate to seed the trabecular layer ([@bib24]). Notably, ERBB2 signaling, which is essential for trabeculation ([@bib29]; [@bib31]), induces EMT in breast cancer cells ([@bib1]; [@bib23]). Altogether, these data indicate that during trabeculation CMs undergo an EMT-like process triggered by ERBB2 signaling.

Cardiac metabolism is essential for energy production to sustain continuous cardiac contractions ([@bib10]). However, the role of metabolism during cardiac development remains unclear. Our study reveals that glycolysis regulates CM behavior during cardiac wall morphogenesis. Glycolysis enables rapid production of ATP to meet the high-energy demands of cell proliferation and migration in developing tissues, cancer cells and endothelial cells ([@bib34]; [@bib30]; [@bib47]). Moreover, glycolytic intermediates are utilized to produce biomass including proteins and nucleic acids, further supporting these processes ([@bib7]; [@bib47]). In addition, excessive glycolysis is associated with EMT in cancer cells ([@bib45]; [@bib22]; [@bib40]). These findings indicate that glycolysis could regulate CM behavior in several different ways, and it will be interesting to dissect these processes further.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                 Source or reference     Identifiers       Additional\
  (species) or resource                                                                                                   information
  --------------------------------- ------------------------------------------- ----------------------- ----------------- -------------
  Genetic reagent (*Danio rerio*)   *pkma2^s717^*                               [@bib54]                                  

  Genetic reagent (*Danio rerio*)   *pkmb^s718^*                                [@bib54]                                  

  Gene (*Danio rerio*)              *pdk3b*                                                             NM_001080688      

  Gene (*Danio rerio*)              *pdha1a*                                                            NM_213393         

  Gene (*Rattus norvegicus*)        *Pdk3*                                                              NM_001106581      

  Gene (*Homo sapiens*)             *ERBB2*                                                             NM_004448         

  Antibody                          anti-Cardiac Troponin I (Goat polyclonal)   Abcam                   AB_880622\        IF(1:500)
                                                                                                        Cat\# ab56357     

  Antibody                          anti-PKM2 (Rabbit monoclonal)               Cell Signaling          AB_1904096\       IF(1:100)\
                                                                                                        Cat\# D78A4       WB(1:1000)

  Chemical compound, drug           Sodium dichloroacetate                      Sigma Aldrich           347795            

  Software, algorithm               Zen 2012 (Blue edition)                     Carl Zeiss Microscopy   Version 1.1.2.0   

  Software, algorithm               Imaris x64                                  Bitplane                Version 9.3.0     

  Other                             DAPI stain                                  Sigma                   D954              (1 µg/mL)
  -------------------------------------------------------------------------------------------------------------------------------------

Zebrafish {#s4-1}
---------

All zebrafish husbandry was performed under standard conditions in accordance with institutional (MPG) and national ethical and animal welfare guidelines. The following transgenic lines and mutants were used: *Tg(myl7:EGFP-Has.HRAS)^s883^* ([@bib6]) abbreviated *Tg(myl7:EGFP-HRAS)*, *Tg(myl7:LIFEACT-GFP)^s974^* ([@bib49]), *Tg(−5.1myl7:DsRed2-NLS*)*^f2Tg^* ([@bib35]) abbreviated *Tg(myl7:nDsRed2)*, *Tg(kdrl:Has.HRAS-mCherry)^s896^* ([@bib3]) abbreviated *Tg(kdrl:HRAS-mCherry)*, *Tg(myl7:cdh2-tdTomato)^bns78^* ([@bib15]), *Tg(myl7:BFP-CAAX)^bns193^* ([@bib18]), *Tg(myl7:mVenus-Gemnn)^ncv43Tg^* ([@bib24]), *pkma*2*^s717^* ([@bib54]) and *pkmb^s718^* ([@bib54]). To generate *Tg(myl7:pdk3b-P2A-tdTomato)^bns365^* and *Tg(myl7:pdha1aSTA-P2A-tdTomato)^bns366^*, *pdk3b* (NM_001080688) and *pdha1a* (NM_213393) were isolated by RT-PCR and cloned under the control of the *myl7* promoter in a vector containing *Tol2* elements and two I-SceI restriction enzyme sites. The following primers were used to amplify the cDNA: *pdk3b* (forward 5'- AAGCAGACAGTGAACAAGCTTCCACCATGAAACTGTTTATCTGCCTACTG-3' and reverse 5'-TAGCTCCGCTTCCGTCGACTCTGTTGACTTTGTATGTGGAC-3'); *pdha1a* (forward 5'-AAGCAGACAGTGAACAAGCTTCCACCATGAGAAAGATGCTAACCATAATT-3' and reverse 5'-TAGCTCCGCTTCCGTCGACGCTGATGGACTTGAGTTTG-3').

To generate the plasmid encoding an activated form of *pdha1a* (*pdha1aSTA*), the equivalent residues for human PDHA1 Ser293 and Tyr301 were replaced by alanine using the following primers: *pdha1aSTA* (forward 5'- CTATCGTTATCATGGACACGCTATGAGCGACCCAGGAGTCAGCGCCCGCACACGTGAGGAGA-3' and reverse 5'- TTCCCTCACGTGTGCGGGCGCTGACTCCTGGGTCGCTCATAGCGTGTCCATGATAACGATAG-3'). Plasmids were then injected into one-cell stage embryos with I-SceI (NEB) or *Tol2* mRNA.

Quantification of CMs in the trabecular layer {#s4-2}
---------------------------------------------

Quantification of trabecular CMs in 77 and 81 hpf heats was performed as previously described ([@bib24]) using the ZEN software (ZEISS). Starting from the mid-sagittal plane, we quantified trabecular versus compact layer CMs in the ventricular outer curvature, 12 planes up and 12 planes down at an increment of 1 μm per plane. To quantify donor-derived trabecular CMs in chimeric hearts generated by cell transplantation, we counted the number of donor-derived trabecular and compact layer CMs. Then, the percentage of donor-derived trabecular CMs was calculated by dividing the number of donor-derived trabecular CMs by the total number of donor-derived CMs. Quantification of trabecular CMs in 131 hpf hearts was performed using the ZEN software (ZEISS). Starting from the mid-sagittal plane, we measured the whole myocardial area as well as the trabecular area, 10 μm up and 10 μm down. Three different sagittal planes per heart were measured. The percentage of the trabecular area for each sagittal plane was calculated by dividing the trabecular area by the myocardial area, and the average value was used for the graph.

In situ hybridization {#s4-3}
---------------------

In situ hybridization was performed as previously described ([@bib56]). To synthesize *pkma* (NM_199333) and *pkmb* (NM_001003488) RNA probes, the following primers were used to amplify the corresponding DNA fragments: *pkma* (forward 5'- TTGGATCCACCATGTCTCAAACTAAAGCTC-3' and reverse 5'- TTTGAATTCTTACGGCACTGGGACGACAC-3'); *pkmb* (forward 5'- TTGGATCCACCATGTCTCAGACAAAGACTA-3' and reverse 5'- TTTGAATTCTCAAGGCACCACAACGATG'). The DNA fragments were cloned into the pCS2 vector. DIG-labeled RNA probes were synthesized using a DIG RNA labeling kit (Sigma-Aldrich) and MegaScript T7 Transcription Kit (Thermo Fisher Scientific).

Pharmacological treatments {#s4-4}
--------------------------

Zebrafish embryos were treated with DMSO (control), 30 mM DCA (Sigma-Aldrich) or 5 μM Erbb2 inhibitor (AG1478; Sigma-Aldrich) from 50 hpf to 77 hpf and then analyzed.

TUNEL assay {#s4-5}
-----------

To examine apoptosis, an in situ cell death detection kit (Roche) was used.

Immunostaining {#s4-6}
--------------

Rat neonatal CMs were fixed in 4% paraformaldehyde. Anti-cardiac troponin I (CTNI) 1:500 (ab56357, Abcam) and anti-PKM2 1:100 (D78A4, Cell Signaling) were used. After washing with PBS, samples were stained with Alexa-568, Alexa-488 or Alexa-647 secondary antibodies 1:500 (Life Technologies), followed by 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI) 1:2000 (Merck) staining to visualize DNA.

Cell culture {#s4-7}
------------

Rat neonatal (P2-P4) CMs were isolated and cultured as previously described ([@bib15]). Cells were plated onto 0.1% gelatin-coated (Sigma) plates and cultured in DMEM/F12 (Gibco) supplemented with 5% horse serum, L-glutamine, Na-pyruvate, penicillin and streptomycin at 37°C and 5% CO~2~. Adenovirus vectors for transfection into CMs were generated using the AdEasy system (Agilent Technologies). To generate adenovirus vectors encoding PDK3 (NM_001106581) or ERBB2 (NM_004448), the following primers were used to amplify *Pdk3* from rat neonatal CM or *ERBB2* from Addgene clone \# 39321: *Pdk3* (forward 5'-TAGAGATCTGGTACCGTCGACCACCATGCGGCTCTTCTACCG-3' and reverse 5'-GGATATCTTATCTAGAAGCTTCTAGAAAGTTTTATTACTCTTGATCTTGTCC-3'); *ERBB2* (forward 5'-TAGAGATCTGGTACCGTCGACGCGGCCGCACCACCATGTATCCATATGATGTTCCAGATTATGCTATGGAGCTGGCGGCCTTG-3' and reverse 5'-GGATATCTTATCTAGAAGCTTTCACACTGGCACGTCCAG).

Imaging {#s4-8}
-------

Zebrafish embryos and larvae were anesthetized with 0.2% tricaine and mounted in 1% low-melting agarose. A Zeiss spinning disk confocal microscope system (CSU-X1, Yokogawa) and ORCA-flash4.0 sCMOS camera (Hamamatsu) was used to acquire images. 3D images were processed using Imaris (Bitplane). Circularity was measured using ImageJ (NIH).

Western blotting {#s4-9}
----------------

Protein expression levels were analyzed by western blotting as previously described ([@bib15]). In brief, proteins were extracted with lysis buffer (150 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.2% SDS, 1 mM EDTA, 5 mM NaF, 0.1 mM orthovanadate, 1 mM phenylmethylsulfonyl fluoride and 1 μg/ml aprotinin). Proteins were separated by SDS-PAGE. The following primary antibodies were used: anti-PKM2 1:1000 (D78A4, Cell Signaling) and anti-alpha-Tubulin 1:1000 (T6199, Sigma).

qPCR {#s4-10}
----

Rat neonatal CMs were transfected with adenovirus vectors encoding genes of interest. 24 hr after transfection, total RNA was extracted. Zebrafish embryos and larvae were treated with DMSO or Erbb2 inhibitor from 55 to 106 hpf, and then the hearts were isolated to extract total RNA. A miRNeasy Mini kit (Qiagen) was used for total RNA extraction and cDNA was synthesized using a SuperScript Second Strand kit (Life Technologies). A CFX Connect Real-Time system (Bio-Rad) and DyNAmo colorFlash SYBR green qPCR kit (ThermoFisher Scientific) were used. Primer sequences are shown in [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"} and Ct values in [Figure 2---source data 3](#fig2sdata3){ref-type="supplementary-material"}.

Metabolic assays {#s4-11}
----------------

The extracellular acidification rate (ECAR) was measured using a Seahorse XFe96 analyzer (Seahorse Bioscience) following manufacturer's protocol. Rat neonatal CMs were seeded at 30,000 cells/well on to 0.1% gelatin-coated XFe96 microplates (Agilent Technologies) in DMEM/F12 (Gibco) containing 10% fetal bovine serum (FBS), L-glutamine, Na-pyruvate, penicillin and streptomycin at 37°C and 5% CO~2~. After 24 hr of culture, the medium was replaced with serum-free medium. Then, cells were transfected with adenovirus vectors encoding genes of interest or a mock adenovirus vector, or treated with NRG1 (100 ng/ml; Abcam). 24 hr after transfection or NRG1 treatment, cells were maintained in non-buffered assay medium (Agilent Technologies) in a non-CO~2~ incubator 1 hr prior to the assay. A glycolysis stress test kit (Seahorse Bioscience) was used to monitor ECAR where baseline measurements were made followed by sequential injection of glucose (10 mM), oligomycin (2 μM), and 2-DG (100 mM).
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This is an elegant study that asks multiple questions about the roles of metabolism in cardiac wall formation and the initiation of trabeculation. Cell transplantations between different genetic/transgenic backgrounds allows detailed analysis of the behavior of cells at the initiation of trabeculation. Overexpression of constitutively active ERRB2 (OE) resulted in upregulation of glycolytic pathway and activity in mouse transgenics, rat neonatal cardiomyocyte cultures, and downregulation of oxidative phosphorylation pathways; the converse was seen with inhibition of Errb2. Multiple approaches, including cardiomyocyte-specific expression of transgenics in zebrafish and *pkma2; pkmb* double mutants, indicate the importance of glycolysis for initiation of trabeculation, downstream of Errb2.

**Decision letter after peer review:**

Thank you for submitting your article \"Metabolic modulation regulates cardiac wall morphogenesis and regeneration in zebrafish\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Marianne Bronner as the Senior and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Shawn Burgess (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Although all of the reviewers are enthusiastic about the manuscript, they concur that it would be important to drop the regeneration component of the manuscript, which feels a bit added on and is not entirely convincing. Other changes are recommended but non-essential. The full reviews are included below for your information.

Reviewer \#1:

Fukuda and colleagues have submitted a manuscript describing the role of metabolic shifts in cardiac development and regeneration. The majority of the work focuses on a particular developmental stage where the inner walls of the heart begin forming from the compact layer via delaminating cardiomyocytes (trabeculation). ErbB2 signaling has been shown to be important for this process and modulation of erbb2 activity levels is the starting point for this manuscript. Across three model systems, increases in ErbB2 activity increases genes related to glycolysis and decreases in ErbB2 signaling have matching decreases in genes involved in glycolysis. The authors targeted specific enzymes modulating pyruvate metabolism, a summary of the results are 1) inhibiting pyruvate dehydrogenase kinase decreases CMs, 2) increasing PDK activity increases CMs, 3) increasing pyruvate dehydrogenase activity decreases CMs, 4) decreasing pyruvate kinase decreases CMs. Shifting attention to cardiac regeneration in adult zebrafish, similar roles for metabolic shifts are seen, inhibition of PDK (with DCA) or phosphoglucose isomerase (2DG) reduces regeneration as does loss of PK activity while loss of ppargc1a (involved in mitochondrial biosynthesis) stimulates regeneration. In general, these are well-controlled experiments that add significantly to our understanding of the relationship between metabolic modulation and embryonic morphogenesis.

There are some problems with conclusions and/or conflicting data that should be addressed.

1\) The authors have focused primarily on enzymes involved in the last steps of glycolysis: the pyruvate dehydrogenase complex (PDC), PDK, and pyruvate kinase (PK). It is true that these enzymes are listed in the glycolysis pathway, but except for PK which does release one ATP molecule, the other enzymes are primarily involved in shunting pyruvate either towards lactic acid (and the pentose phosphate pathway) or into the TCA cycle. This shift point isn\'t really modulating glycolysis but the choice between aerobic and anaerobic respiration and it may be that pyruvate concentration and/or utilization is the key step they are looking at and not glycolysis per se. I am arguing this point because otherwise the loss of PK activity (*pkma2/pkmb*) resulting in less trabeculation and regeneration appears to conflict with the other observations. Increasing PDK activity pushes pyruvate towards lactate (shunting away from mitochondria) resulting in an increase in trabeculation, blocking PDK activity has the opposite effect, less trabeculation more TCA cycle. The dominant active pyruvate dehydrogenase experiments are also consistent with these results, more PDK activity = less trabeculation. The PK knockouts should also reduce the availability of pyruvate for the mitochondria, yet it results in less trabeculation and less regeneration. Perhaps lactate is a key signaling molecule? This has been shown in neurons for example.

2\) I think the authors need to change the general use of glycolysis throughout the manuscript to specify whether they are talking about anaerobic or aerobic glycolysis. Can the redox state be determined during trabeculation?

Reviewer \#2:

There are a few questions about the trabeculation results, but overall this part of the study is convincing and an important contribution to the heart development field. In contrast, there are significant concerns about the heart regeneration aspects of the paper.

1\) The interpretation that cardiac regeneration is altered is not convincing. The assays for regeneration were only taken to 5 days post cryo injury (dpci), which is not sufficient time to assess whether regeneration is normal or abnormal. The hearts in any of the experimental cohorts could be slightly delayed and then fully recovered by 30 dpci. There is an additional concern that the recovering fish are heat shocked every day for the first five days up to analysis. The standard in the field is 30- or 60-days post injury, with intermittent time points. I suggest removing the regeneration aspect of this paper. It is just too premature, unsupported conclusions in the title and Abstract could be incorrect.

2\) In Figure 4, cell transplantation is used to generate chimeric hearts is a very useful experiment. I imagine the numbers are in hand, but it would be useful to see them analyzed in a few different ways. Are the total number of trabecular cardiomyocytes decreased in the hearts that received mutant donor cells? Or is it just a shift between the mutant vs. host cells that can contribute to the trabeculae? Figure 4C indicates that the% of cardiomyocytes that are trabecular was decreased in hearts that received homozygous mutant cells. However, it does not tell us whether the cardiomyocytes that are trabecular are from the transplanted or host cells. The legend says \'percentage of donor CMs\' However, Figure 4B\' appears to show some labeled (transplant) cells that are interior (trabecular), outside the white box. It would be useful to know the number of labeled (transplant) vs. unlabeled (host) cells that are trabecular, to understand whether the effect is cell autonomous or non-autonomous.

3\) In Supplementary Figure 5, it appears that mCherry is also expressed in the epicardium after TAM and HS treatment. If this is the case, interpretation of results will need modification.

Reviewer \#3:

In this manuscript, Fukuda et al. describe a role for glucose metabolism in not only normal development of the trabeculated myocardium, but also in the successful regeneration of the adult heart. Much is known about metabolic processes in the adult heart; here, the authors present a previously understudied role of glycolysis during development. First, by chimeric analysis to produce a higher-resolution look by live imaging, the authors show that cardiomyocytes elicit changes in cell shape to properly develop a trabeculated myocardium. Furthermore, the authors show Nrg1/Erbb2 signaling is required for trabeculation and activates glycolysis, which regulates development of the trabecular myocardium. Finally, the authors extend their study to adulthood and show that glycolysis is essential for successful dedifferentiation and proliferation of cardiomyocytes in cryoinjured adult hearts by upregulation of glycolytic enzymes at the wound border after injury. Overall, the authors contribute a new understanding of the role of glycolysis in proper heart development and repair.

1\) The authors describe cell shape changes and membrane protrusions of cardiomyocytes to enter the trabecular layer. While the images are that of live embryos, this argument would be strengthened by time-lapse imaging to track the individual cardiomyocytes changing shape and position over time.

2\) Methods used to determine glycolytic activity by assaying extracellular acidification rate should be explained in more detail.

3\) The authors use transplanted double heterozygous and double mutant cells to show double mutant cells cannot incorporate into trabeculae. While these are very careful experiments, the health of these cells after transplantation is a concern. Have the authors scored transplant survival? Or performed a TUNEL assay to ensure the mutant cells are not dying after transplantation? Is delamination the only cellular event (cell motility, shape change, membrane protrusions, etc) that is perturbed?

4\) Ppargc1a regulates genes involved in OXPHOS and are absent from regenerating hearts, but are they present in uninjured hearts by in situ?
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Author response

Reviewer \#1:

\[...\] There are some problems with conclusions and/or conflicting data that should be addressed.

> 1\) The authors have focused primarily on enzymes involved in the last steps of glycolysis: the pyruvate dehydrogenase complex (PDC), PDK, and pyruvate kinase (PK). It is true that these enzymes are listed in the glycolysis pathway, but except for PK which does release one ATP molecule, the other enzymes are primarily involved in shunting pyruvate either towards lactic acid (and the pentose phosphate pathway) or into the TCA cycle. This shift point isn\'t really modulating glycolysis but the choice between aerobic and anaerobic respiration and it may be that pyruvate concentration and/or utilization is the key step they are looking at and not glycolysis per se. I am arguing this point because otherwise the loss of PK activity (pkma2/pkmb) resulting in less trabeculation and regeneration appears to conflict with the other observations. Increasing PDK activity pushes pyruvate towards lactate (shunting away from mitochondria) resulting in an increase in trabeculation, blocking PDK activity has the opposite effect, less trabeculation more TCA cycle. The dominant active pyruvate dehydrogenase experiments are also consistent with these results, more PDK activity = less trabeculation. The PK knockouts should also reduce the availability of pyruvate for the mitochondria, yet it results in less trabeculation and less regeneration. Perhaps lactate is a key signaling molecule? This has been shown in neurons for example.

The mammalian *Pkm* gene gives rise to two splice isoforms, *Pkm1* and *Pkm2*. The zebrafish genome contains two *pkm* genes, *pkma* and *pkmb. pkma* encodes both an orthologue of mammalian *Pkm1 (pkma1*) and an orthologue of mammalian *Pkm2 (pkma2*), while *pkmb* encodes only another orthologue of mammalian *Pkm2* (Stone et al., 2018).

Expression of PKM2 is associated with metabolism of pyruvate to lactate. Loss of PKM2 has been shown to result in compensatory upregulation of PKM1, which drives enhanced mitochondrial metabolism of pyruvate (Christofk et al., 2008; Lunt et al., 2015; Zheng et al., 2016). Therefore, with respect to pyruvate metabolism, the loss of PKM2 mimics blocking PDK activity, whereas the loss of PKM1 mimics enhancing PDK activity. In *pkma2; pkmb* double mutant zebrafish, the *pkma1* isoform, which drives pyruvate metabolism via OXPHOS, remains intact. Thus, in *pkma2; pkmb* double mutant zebrafish we expect a reduction in the metabolism of pyruvate to lactate and an increase in pyruvate oxidation, similar to the situation observed following inhibition of PDK activity. These findings are consistent with the other models that have been analyzed (Christofk et al., 2008; Zheng et al., 2016).

The revised sentence reads as follows:

'We examined *pkma2; pkmb* double mutants in which Pkma1, which drives pyruvate metabolism via OXPHOS, remains intact, and found that loss of *pkma2* and *pkmb* impaired trabeculation (Figure 4---figure supplement 1C).'

> 2\) I think the authors need to change the general use of glycolysis throughout the manuscript to specify whether they are talking about anaerobic or aerobic glycolysis.

Although PKM2 (Christofk et al., 2008) and PDK (Takubo et al., 2013) play an important role during aerobic glycolysis (Vander Heiden et al., 2009; Lunt and Vander Heiden, 2011), we did not assess oxygen levels in our models, and thus prefer to use "glycolysis".

> Can the redox state be determined during trabeculation?

We have now examined the redox state using the cardiomyocyte specific reporter line previously used to examine hydrogen peroxide levels (Panieri et al., 2017). We found no significant difference in reporter activity between compact and trabecular cardiomyocytes during delamination ([Author response image 1](#respfig1){ref-type="fig"}).

![Redox analysis.\
70 hpf *Tg(myl7:mitochondrial-Rogofp2Orp1)* hearts were examined and 405 nm/488 nm ratios determined for redox state analysis. Relative values of 405 nm/488 nm in compact and trabecular cardiomyocytes are shown.](elife-50161-resp-fig1){#respfig1}

Reviewer \#2:

> There are a few questions about the trabeculation results, but overall this part of the study is convincing and an important contribution to the heart development field. In contrast, there are significant concerns about the heart regeneration aspects of the paper.
>
> 1\) The interpretation that cardiac regeneration is altered is not convincing. The assays for regeneration were only taken to 5 days post cryo injury (dpci), which is not sufficient time to assess whether regeneration is normal or abnormal. The hearts in any of the experimental cohorts could be slightly delayed and then fully recovered by 30 dpci. There is an additional concern that the recovering fish are heat shocked every day for the first five days up to analysis. The standard in the field is 30- or 60-days post injury, with intermittent time points. I suggest removing the regeneration aspect of this paper. It is just too premature, unsupported conclusions in the title and Abstract could be incorrect.

We have now removed the regeneration part from the revised manuscript.

> 2\) In Figure 4, cell transplantation is used to generate chimeric hearts is a very useful experiment. I imagine the numbers are in hand, but it would be useful to see them analyzed in a few different ways. Are the total number of trabecular cardiomyocytes decreased in the hearts that received mutant donor cells? Or is it just a shift between the mutant vs. host cells that can contribute to the trabeculae? Figure 4C indicates that the% of cardiomyocytes that are trabecular was decreased in hearts that received homozygous mutant cells. However, it does not tell us whether the cardiomyocytes that are trabecular are from the transplanted or host cells. The legend says \'percentage of donor CMs.\' However, Figure 4B\' appears to show some labeled (transplant) cells that are interior (trabecular), outside the white box. It would be useful to know the number of labeled (transplant) vs. unlabeled (host) cells that are trabecular, to understand whether the effect is cell autonomous or non-autonomous.

We have now counted the total number of trabecular cardiomyocytes in the chimeric hearts and no significant differences were observed compared to WT (Figure 4---figure supplement 1D).

In Figure 4C, we counted the number of donor-derived cardiomyocytes in both the trabecular and compact layers of the chimeric hearts. We then calculated the percentage of donor-derived trabecular CMs by dividing the number of donor-derived trabecular CMs by the total number of donor-derived CMs. To clarify this point we have now modified Figure 4C, its legend and the relevant part of the Materials and methods section in the revised manuscript.

Together, our data indicate cardiomyocyte-autonomous function of *pkma2* and *pkmb* during trabeculation.

> 3\) In Supplementary Figure 5, it appears that mCherry is also expressed in the epicardium after TAM and HS treatment. If this is the case, interpretation of results will need modification.

We have now removed the regeneration part from the revised manuscript.

Reviewer \#3:

> \[...\] 1) The authors describe cell shape changes and membrane protrusions of cardiomyocytes to enter the trabecular layer. While the images are that of live embryos, this argument would be strengthened by time-lapse imaging to track the individual cardiomyocytes changing shape and position over time.

Time-lapse imaging to track individual cardiomyocytes during trabeculation has been shown in a previous paper (Staudt et al., 2014). However, the 3D morphology of single cardiomyocytes that enter the trabecular layer remains mostly unclear, which is why we examined it.

> 2\) Methods used to determine glycolytic activity by assaying extracellular acidification rate should be explained in more detail.

We have now modified the Materials and methods section in the revised manuscript to address the reviewer's comment.

> 3\) The authors use transplanted double heterozygous and double mutant cells to show double mutant cells cannot incorporate into trabeculae. While these are very careful experiments, the health of these cells after transplantation is a concern. Have the authors scored transplant survival? Or performed a TUNEL assay to ensure the mutant cells are not dying after transplantation?

We have now performed TUNEL assays and no elevated levels of apoptosis were detected in *pkma2; pkmb* mutant cardiomyocytes in chimeric hearts compared to WT cardiomyocytes (Figure 4---figure supplement 1D).

> Is delamination the only cellular event (cell motility, shape change, membrane protrusions, etc) that is perturbed?

NRG/ERBB signaling also regulates cardiomyocyte proliferation (Zhao et al., 1998; Grego-bessa et al., 2007; Bersell et al., 2009; Rasouli and Stainier, 2017). We have now counted the number of proliferating cardiomyocytes during trabeculation and these data indicate that modulation of metabolism does not appear to affect cardiomyocyte proliferation (Figure 3---figure supplement 1B).

> 4\) Ppargc1a regulates genes involved in OXPHOS and are absent from regenerating hearts, but are they present in uninjured hearts by in situ?

We have now removed the regeneration part from the revised manuscript.
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